Japanese Regulators Have Approved AstraZeneca Lung Cancer Drug

AstraZeneca announced Tuesday that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), following priority review. The approval is based on results from the global Phase III FLAURA trial which included Japanese patients and which were published in the New England Journal of Medicine.


Sign In For Unlimited Access

Please log in, or sign up for a new account and choose a subscription to continue reading.

Register


About Staff Writer

First State Update's Delaware editorial team covers New Castle County, Kent County and Sussex County breaking news, political news, and general news stories. We bring the reader the latest news from the Wilmington, Newark, Dover, Rehoboth Beach and all point in between. If you have news to share, email us at desk@firststateupdate.com.

View all posts by Staff Writer →